CompletedNot Applicable

Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.

Taiwan110 participantsStarted 2013-09

Plain-language summary

Our pilot results showed that meperidine reduce patient discomfort during EGD (esophagogastroduodenoscopy). But many patients can tolerate EGD well without any sedative agents. So the investigators target the use of meperidine on patients expected to have poor tolerance in this study, which includ young females with high anxiety level and patients with prior poor tolerance. The investigators test the hypothesis that meperidine improves tolerance and alleviates discomfort for patients expected to have poor tolerance during diagnostic EGD.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * female youger than 65 years with high anxiety level * patients with previous poor tolerance of EGD Exclusion Criteria: * a therapeutic EGD * sedation with other agents * contraindication to Buscopan (hyoscine N-butylbromide) or meperidine * American Society of Anesthesiology (ASA) risk Class 3 or higher, renal failure * age less than 20 years or more than 80 years * pregnancy * refusal to provide written informed consent. All participants signed written informed consents

What they're measuring

discomfort score during esophageal intubation

Timeframe: 10 minutes

Trial details

NCT IDNCT01948921

SponsorDalin Tzu Chi General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-03

View on ClinicalTrials.gov More Patients Undergoing Diagnostic EGD trials